MacroGenics announces partial clinical hold on MGD009 phase 1 studies
MacroGenics announced that on Dec 6, it received a letter from the FDA indicating that a partial clinical hold has been placed on its Phase 1 monotherapy study of MGD009, a B7-H3 × CD3 bispecific DART® molecule, as well as on a combination study of MGD009 and MGA012 (anti-PD-1). December 07, 2018